Publication:
Learning from Prozac: A Case Study on Reforming the FDA Drug Approval Process

Thumbnail Image

Date

1997

Published Version

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Learning from Prozac: A Case Study on Reforming the FDA Drug Approval Process (1997 Third Year Paper)

Research Data

Abstract

The law, focused as it is on making final determinations and settling issues one way or another, continually lags behind science, which concentrates on an evolving understanding of various phenomena through constant enhancement of current understandings of existing realities. Thus, a drug approval process, which obviously deals with scientific issues of drug development, cannot always keep pace with scientific understandings of drug development. The law is flexible and capable of accommodating new understandings, though; therefore, consideration of the scientific issues involved in drug development and approval is appropriate and ought to be undertaken as much as possible in order to develop legal answers that are as accurate as they can be at any given time.

Description

Other Available Sources

Keywords

Food and Drug Law, prozac, regulatory reform, prescription drug licensure, human drugs, FDA approval process

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories